Partial responses to vemurafenib in patients with BRAF V600E–mutated colorectal cancer have previously been reported in the literature.23 The absence of TP53 mutations and PI3K pathway alterations in these patients may explain the partial response to vemurafenib,24 although this remains speculative. This evidence concerns the gene TP53 and colorectal cancer.